Antares Pharma Inc  

(Public, NASDAQ:ATRS)   Watch this stock  
Find more results for ATRS
1.85
+0.01 (0.82%)
Real-time:   10:16AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.83 - 1.90
52 week 1.82 - 5.15
Open 1.83
Vol / Avg. 93,784.00/984,018.00
Mkt cap 240.71M
P/E     -
Div/yield     -
EPS -0.23
Shares 130.47M
Beta 0.39
Inst. own 36%
Nov 4, 2014
Q3 2014 Antares Pharma Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 10, 2014
Antares Pharma Inc at Morgan Stanley Healthcare Conference
Aug 7, 2014
Q2 2014 Antares Pharma, Inc. Earnings Release
Aug 7, 2014
Q2 2014 Antares Pharma Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -143.80% -99.46%
Operating margin -143.69% -101.12%
EBITD margin - -98.42%
Return on average assets -42.98% -22.23%
Return on average equity -61.20% -26.08%
Employees 60 -
CDP Score - -

Address

SUITE 300, 100 PRINCETON SOUTH
EWING, NJ 08628
United States - Map
+1-609-3593020 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Antares Pharma, Inc. (Antares) is a pharma company that focuses on self-injection pharmaceutical products and technologies and topical gel-based products. The Company�s subcutaneous and intramuscular injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision reusable needle-free injectors, and disposable multi-use pen injectors. In the injector area, it has licensed its reusable needle-free injection device for use with human growth hormone (hGH) to Teva, Ferring Pharmaceuticals BV (Ferring) and JCR Pharmaceuticals Co., Ltd. (JCR), with Teva and Ferring being its two primary customers. The Company has also licensed both disposable auto and pen injection devices to Teva for use in certain fields and territories and is engaged in product development activities for Teva utilizing these devices. In the gel-based area, it received Food and Drug Administration (FDA) approval in December 2011 for its oxybutynin gel 3% product, Anturol.

Officers and directors

Leonard S. Jacob M.D., Ph.D Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Eamonn P. Hobbs President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Robert F. Apple CPA Chief Financial Officer, Chief Operating Officer, Executive Vice President, President - Parenteral Products Division
Age: 47
Bio & Compensation  - Reuters
Jennifer Evans Stacey Esq. Senior Vice President, General Counsel, Human Resources and Secretary
Bio & Compensation  - Reuters
Robert P. Roche Jr. Director
Age: 58
Bio & Compensation  - Reuters
Marvin Samson Director
Age: 72
Bio & Compensation  - Reuters
Thomas J. Garrity Independent Director
Age: 65
Bio & Compensation  - Reuters
Jacques Gonella Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Anton G. Gueth Independent Director
Age: 57
Bio & Compensation  - Reuters